Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Therapeutic Potentials of Adenosine Receptors: The State of The Art

Author(s): Pran Kishore Deb

Volume 25, Issue 26, 2019

Page: [2789 - 2791] Pages: 3

DOI: 10.2174/138161282526191007143942

Next »
[1]
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: The state of the art. Physiol Rev 2018; 98: 1591-625.
[2]
Borea PA, Gessi S, Merighi S, Varani K. Adenosine as a multi-signalling guardian angel in human diseases: When, where and how does it exert its protective effects? Trends Pharmacol Sci 2016; 37: 419-34.
[3]
Newby AC. Adenosine and the concept of ‘retaliatory metabolites’. Trends Biochem Sci 1984; 9: 42-4.
[4]
Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 2005; 67: 1385-7.
[5]
Chen J-F, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov 2013; 12: 265.
[6]
Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 299-309.
[7]
Deussen A. Metabolic flux rates of adenosine in the heart. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 351-63.
[8]
Deussen A, Bading B, Kelm M, Schrader J. Formation and salvage of adenosine by macrovascular endothelial cells. Am J Physiol 1993; 264: H692-700.
[9]
Deussen A, Stappert M, Schäfer S, Kelm M. Quantification of extracellular and intracellular adenosine production: Understanding the transmembranous concentration gradient. Circulation 1999; 99: 2041-7.
[10]
Gracia E, Farré D, Cortés A, et al. The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. FASEB J 2013; 27: 1048-61.
[11]
Pacheco R, Martinez-Navio J, Lejeune M, et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci USA 2005; 102: 9583-8.
[12]
Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-52.
[13]
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 2011: pr. 110.003285.
[14]
Borea PA, Varani K, Gessi S, Merighi S, Vincenzi F. The Adenosine Receptors. Springer 2018.
[15]
Fredholm BB. Adenosine-a physiological or pathophysiological agent? J of Mol Med 2014; 92: 201-6.
[16]
Merighi S, Gessi S, Borea PA. Adenosine receptors: Structure, distribution, and signal transduction. In: ed., The Adenosine Receptors. Springer, 2018; pp. 33-57.
[17]
Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006; 5: 247.
[18]
Deb PK, Deka S, Borah P, Abed SN, Klotz K-N. Medicinal chemistry and therapeutic potential of agonists, antagonists and allosteric modulators of A1 adenosine receptor: Current status and perspectives. Curr Pharm Des 2019; 25(25): 2697-715.
[19]
Al-Attraqchi O, Attimarad M, Venugopala K, Nair A, Al-Attraqchi N. Adenosine A2A receptor as a potential drug target-current status and future perspectives. Curr Pharm Des 2019; 25(25): 2716-40.
[20]
Chandrasekaran B, Samarneh S, Jaber AMY, Kassab G, Agrawal N. Therapeutic potentials of A2B adenosine receptor ligands: Current status and perspectives. Curr Pharm Des 2019; 25(25): 2741-71.
[21]
Mailavaram RP, Al-Attraqchi O, Kar S, Ghosh S. Current status in the design and development of agonists and antagonists of adenosine A3 receptor as potential therapeutic agents. Curr Pharm Des 2019; 25(25): 2772-87.
[22]
Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: Translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 2008; 108: 238-63.
[23]
Deb PK, Balakumar C, Rao AR, Roy PP, Roy K. QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A3 receptor subtype. Bioorg Med Chem Lett 2011; 21: 818-23.
[24]
Deb PK, Chandrasekaran B, Mailavaram R, Tekade RK, Jaber AMY. Molecular modeling approaches for the discovery of adenosine A2B receptor antagonists: Current status and future perspectives. Drug Discov Today 2019.
[25]
Deb PK. Recent updates in the computer aided drug design strategies for the discovery of agonists and antagonists of adenosine receptors. In: ed. Bentham Science, 2019; pp. 747-749.
[26]
Shaik K, Deb PK, Mailavaram RP, et al. 7-Amino-2-aryl/heteroaryl-5-oxo-5,8-dihydro[1,2,4]triazolo[1,5‐a]pyridine‐6‐carbonitriles: Synthesis and adenosine receptor binding studies. Chem Biol Drug Des 2019; 94: 1568-73.
[27]
Deb PK, Mailavaram R, Chandrasekaran B, et al. Synthesis, adenosine receptor binding and molecular modelling studies of novel thieno[2,3‐d]pyrimidine derivatives. Chem Biol Drug Des 2018; 91: 962-9.
[28]
Chandrasekaran B, Deb PK, Kachler S, Akkinepalli RR, Mailavaram R, Klotz K-N. Synthesis and adenosine receptors binding studies of new fluorinated analogues of pyrido [2,3-d] pyrimidines and quinazolines. Med Chem Res 2018; 27: 756-67.
[29]
Balakumar C, Kishore DP, Rao KV, et al. Design, microwave-assisted synthesis and in silico docking studies of new 4H-pyrimido[2, 1-b]benzothiazole-2-arylamino-3-cyano-4-ones as possible adenosine A2B receptor antagonists. Indian J Chem 2012; 51B: 1105-13.
[30]
Gessi S, Merighi S, Varani K, Borea PA. Adenosine receptors in health and disease. In: ed. Advances in pharmacology. Elsevier, 2011; pp. 41-75.
[31]
Borah P, Deka S, Mailavaram RP, Deb PK. P1 receptor agonists/antagonists in clinical trials-potential drug candidates of the future. Curr Pharm Des 2019; 25(26): 2792-807.
[32]
Choudhury H, Chellappan DK, Sengupta P, Pandey M, Gorain B. Adenosine receptors in modulation of central nervous system disorders. Curr Pharm Des 2019; 25(26): 2808-27.
[33]
Gorain B, Choudhury H, Yee GS, Bhattamisra SK. Adenosine receptors as novel targets for the treatment of various cancers. Curr Pharm Des 2019; 25(26): 2828-41.
[34]
Marwein S, Mishra B, De Chandra U, Acharya PC. Recent progress of adenosine receptor modulators in the development of anticancer chemotherapeutic agents. Curr Pharm Des 2019; 25(26): 2842-58.
[35]
Pal Y, Bandyopadhyay N, Pal RS, Ahmed S, Bandopadhyay S. Perspective and potential of A2A and A3 adenosine receptors as therapeutic targets for the treatment of rheumatoid arthritis. Curr Pharm Des 2019; 25(26): 2859-74.
[36]
Shakya AK, Naik RR, Almasri IM, Kaur A. Role and function of adenosine and its receptors in inflammation, neuroinflammation, IBS, autoimmune inflammatory disorders, rheumatoid arthritis and psoriasis. Curr Pharm Des 2019; 25(26): 2875-91.
[37]
Jamwal S, Mittal A, Kumar P, Alhayani DM, Al-Aboudi A. Therapeutic potential of agonists and antagonists of A1, A2a, A2b and A3 adenosine receptors. Curr Pharm Des 2019; 25(26): 2892-905.

Rights & Permissions Print Cite
Article Metrics
19
4
© 2024 Bentham Science Publishers | Privacy Policy